Picture of Terrascend logo

TSND — Terrascend News Story

0.000.00%
ca flag iconLast trade - 00:00
Consumer DefensivesSpeculativeSmall CapContrarian

Canada's TerrAscend Q4 revenue beats estimates

Overview

Canada cannabis firm's Q4 revenue beat analyst expectations

Company renewed share buyback program for up to $10 mln USD during the year

Outlook

TerrAscend says it expects sustainable growth and shareholder value in 2026 and beyond

TerrAscend plans to focus M&A strategy on accretive transactions aligned with strategic goals

Result Drivers

WHOLESALE AND PRODUCT PERFORMANCE - Co cited sequential increases in both retail and wholesale revenue, with branded products ranking highly in Maryland and Pennsylvania

Company press release: ID:nGNX62XBPy

Key Details

MetricBeat/MissActualConsensus Estimate
Q4 RevenueBeat$66.10 mln$64.68 mln (4 Analysts)
Q4 Gross Margin52.1%
Q4 Net Income from Cont. Ops-$500,000
Analyst Coverage The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell" The average consensus recommendation for the drug retailers peer group is "buy" Wall Street's median 12-month price target for Terrascend Corp is C$2.00, about 119.8% above its March 11 closing price of C$0.91 For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com. (This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Recent news on Terrascend

See all news